Last reviewed · How we verify
Pro Top & Mediking Company Limited — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Trabeculectomy with MMC | Trabeculectomy with MMC | marketed | Ophthalmology | |||
| MMC in glaucoma filtering surgery | MMC in glaucoma filtering surgery | phase 3 | Antiproliferative agent / Antimetabolite | DNA (cross-linking agent) | Ophthalmology | |
| MMC in Trabeculectomy | MMC in Trabeculectomy | phase 3 | Alkylating agent / Antimetabolite | DNA cross-linking agent | Ophthalmology |
Therapeutic area mix
- Ophthalmology · 3
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Pro Top & Mediking Company Limited:
- Pro Top & Mediking Company Limited pipeline updates — RSS
- Pro Top & Mediking Company Limited pipeline updates — Atom
- Pro Top & Mediking Company Limited pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Pro Top & Mediking Company Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pro-top-mediking-company-limited. Accessed 2026-05-18.